Skip to main content

Table 2 Characteristics and clinical presentation of 16 previously reported cases and our two cases

From: Peritonitis due to Mycobacterium abscessus in peritoneal dialysis patients: case presentation and mini-review

Case

Country

Age/sex

AFB test

Days to initiate NTM treatment from onset

Route of infection

History of topical GM

Peak cell count of effluent (/μL)

Antibiotics (duration)

Catheter removal

Complication

Prognosis

Ref

1

Japan

59/F

(−)

18

ESI, TI

(+)

1700

AZM (1 week)

CAM (22 weeks)

AMK (22 weeks)

IPM/CS (23 weeks)

(+)

Abscess

HD

Case 1

2

Japan

67/M

(−)

5

ESI, TI

(+)

480

CAM (28 weeks)

AMK (28 weeks)

IPM/CS (6 weeks)

MFLX (20 weeks)

(+)

Abscess/EPS

HD

Case 2

3

Hong Kong

39/F

N/A

N/A

ESI

(+)

N/A

AMK (8 weeks)

CAM (28 weeks)

MEPM (4 weeks)

(+)

Abscess

HD

[4]

4

Hong Kong

45/M

N/A

N/A

ESI

(+)

N/A

AMK (4 weeks)

MFLX (20 weeks)

AZM (6 weeks)

(+)

(−)

Resuming PD

[4]

5

Taiwan

44/F

(+)

28

ESI

(−)

53,512

CAM (165 days)

AMK (68 days)

MEPM (165 days)

LVFX (111 days)

(+)

Abscess

Death

[5]

6

Taiwan

58/F

(+)

3

ESI, TI

(−)

286

IPM/CS (70 days)

AMK (50 days)

CAM (234 days)

CPFX (217 days)

DOXY (180 days)

(+)

Abscess

HD

[5]

7

Singapore

70/M

(−)

12

N/A

(−)

993

MEPM (N/A)

CAM (4 weeks)

AMK (4 weeks)

(+)

Abscess

Death

[6]

8

Singapore

50/M

(−)

9

ESI

(−)

1715

CAM (12 weeks)

CPFX (12 weeks)

(+)

(−)

HD

[6]

9

Singapore

56/M

(−)

10

ESI, TI

(−)

115

CAM (12 weeks)

AMK (6 weeks)

(+)

(−)

Death

[6]

10

Singapore

60/F

(+)

7

ESI, TI

(−)

146

CAM (12 weeks)

AMK (6 weeks)

(+)

(−)

Resuming PD

[6]

11

Japan

51/F

(+)

6

ESI, TI

(−)

1200

CAM (7 weeks)

CPFX (3 weeks)

AMK (3 weeks)

(+)

Abscess

HD

[7]

12

Saudi Arabia

60/F

(+)

10

ESI, TI

(−)

180

CAM (8 weeks)

AMK (8 weeks)

(+)

(−)

HD

[8]

13

Saudi Arabia

64/F

(+)

6

N/A

(−)

214

CAM (12 weeks)

(+)

(−)

HD

[8]

14

Australia

49/M

N/A

N/A

N/A

N/A

N/A

CEZ (N/A)

(+)

EPS

Death

[9]

15

Australia

40/F

N/A

N/A

N/A

N/A

N/A

AMK (N/A)

Cefoxitin (N/A)

(+)

(−)

N/A

[9]

16

Australia

65/M

N/A

N/A

N/A

N/A

N/A

Ticarcillin (N/A)

VCM (N/A)

GM (N/A)

(+)

(−)

N/A

[9]

17

The Netherlands

73/F

N/A

34

ESI

N/A

N/A

TGC (N/A)

CAM (N/A)

IPM/CS (N/A)

(+)

(−)

Death

[10]

18

USA

67/M

(+)

7

N/A

(−)

1647

AMK (12 weeks)

CAM (12 weeks)

(+)

(−)

HD

[11]

  1. This table was based on the work by Yang et al. as a reference [5]. AFB, acid-fast bacilli, AMK amikacin, AZM azithromycin, CAM clarithromycin, CEZ cefazolin, CPFX ciprofloxacin, DOXY doxycycline, EPS encapsulating peritoneal sclerosis, ESI exit-site infection, F female, GM gentamicin, HD hemodialysis, IPM/CS imipenem/cilastatin, LVFX levofloxacin, M male, MEPM meropenem, MFLX moxifloxacin, N/A not applicable, NTM nontuberculous mycobacteria, PD peritoneal dialysis, Ref references, TI tunnel infection, TGC tigecycline, VCM vancomycin, w week
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us